Background: Despite data derived from observational studies, optimal anticoagulation strategies have yet to be established for patients with nonvalvular atrial fibrillation and obesity.
Objective: To describe direct oral anticoagulant (DOAC) regimens prescribed for adult patients with nonvalvular atrial fibrillation who weighed more than 120 kg.
Methods: This single-centre, retrospective cohort study, conducted in the Saskatchewan Health Authority - Regina Area, involved adult patients with body weight greater than 120 kg who had an indication for oral anticoagulation to treat nonvalvular atrial fibrillation and were discharged by a cardiologist between June 2019 and July 2021.
Results: A total of 62 patients were included (median weight 135 kg). At discharge, DOACs were prescribed for 57 (92%) of the patients and warfarin for 5 (8%). In numeric terms, patients receiving warfarin were at higher risk of thromboembolism or thrombosis; however, the small sample size limited the ability to draw conclusions.
Conclusions: Practice patterns in the Saskatchewan Health Authority - Regina Area indicated substantial use of DOACs for patients with body weight greater than 120 kg; however, for those with the highest weights, warfarin was still in use.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10914393 | PMC |
| http://dx.doi.org/10.4212/cjhp.3425 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical effectiveness and safety comparison between direct oral anticoagulants and warfarin for nonvalvular atrial fibrillation patients following percutaneous left atrial appendage closure operation intervention: a prospective observational study.
BMC Pharmacol Toxicol
January 2025
Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
The main objective of this study was to investigate the optimal post-left atrial appendage closure (LAAC) anticoagulation strategy, focusing on minimizing device-related thrombosis (DRT) and thromboembolism (TE) events without increasing bleeding risk. After successful LAAC, consecutive participants were treated with 45-day anticoagulants (rivaroxaban 15 mg daily, dabigatran 110 mg twice a day, and warfarin). The efficacy endpoints included DRT, TE, and hospital readmissions due to cardiac caused, while safety endpoints encompassed bleeding events, monitored over a 12-month follow-up period.
View Article and Find Full Text PDFImpact of delayed adoption of novel atrial fibrillation treatments.
Am J Manag Care
December 2024
Center for Healthcare Economics and Policy, FTI Consulting, 350 S Grande Ave, Los Angeles, CA 90071. Email:
Objective: To examine the relationship between adoption of direct oral anticoagulants (DOACs) and health and cost outcomes for patients with nonvalvular atrial fibrillation.
Study Design: Real-world cohort study.
Methods: US adults who newly initiated treatment for nonvalvular atrial fibrillation were identified from claims data.
Adding Insult to Injury: When Atrial Fibrillation Encounters Left Bundle Branch Block.
Rev Cardiovasc Med
December 2024
Department of Cardiology, The First Affiliated Hospital with Nanjing Medical University, 210029 Nanjing, Jiangsu, China.
Background: It is not uncommon that atrial fibrillation (AF) coexists with left bundle branch block (LBBB). Whether LBBB is an independent predictor of poor prognosis in AF patients remains undetermined. This study aims to investigate the impact of LBBB on the AF-related outcomes in non-valvular AF patients.
View Article and Find Full Text PDFComparative Endothelialization of the Watchman Plug Device and LACBES Pacifier Occluder after Left Atrial Appendage Closure.
Rev Cardiovasc Med
December 2024
Department of Cardiology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, 200011 Shanghai, China.
Article Synopsis
- Left atrial appendage closure (LAAC) is an alternative for patients with nonvalvular atrial fibrillation (NVAF) to avoid oral anticoagulants, but issues like incomplete device endothelialization (IDE) can lead to complications.
- A study compared the endothelialization rates after implantation of two devices: the Watchman plug and the LACBES occluder, in 201 patients, using cardiac computed tomography angiography (CCTA).
- Results showed that the LACBES occluder had a higher IDE rate at both 3 and 6 months compared to the Watchman device, indicating that it takes longer for the LACBES to achieve complete endothelialization after LAAC.
Role of a new inflammation predictor in predicting recurrence of atrial fibrillation after radiofrequency catheter ablation.
World J Cardiol
December 2024
Department of Arrhythmia, Weifang People's Hospital, Weifang 261000, Shandong Province, China.
Background: Radiofrequency catheter ablation (RFCA) has become an important strategy for treating atrial fibrillation (AF), and postoperative recurrence represents a significant and actively discussed clinical concern. The recurrence after RFCA is considered closely related to inflammation. Systemic immune inflammation index (SII) is a novel inflammation predictor based on neutrophils, platelets, and lymphocytes, and is considered a biomarker that comprehensively reflects the immune inflammatory status of the body.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!